NCT05522998CompletedPhase 4
Efficacy and Safety of Ciprofol in Laparoscopic Sleeve Gastrectomy
Efficacy and Safety of Ciprofol for the Induction of General Anesthesia in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy
Source: ClinicalTrials.gov · Last updated 28 Aug 2024
Brief summary (registry, in English)
To evaluate the efficacy and safety of ciprofol for the induction of general anesthesia in obese patients undergoing laparoscopic sleeve gastrectomy. A randomized, parallel, propofol injection positive control study will be conducted to select obese patients who will undergo laparoscopic sleeve gastrectomy in the author's hospital. To evaluate the efficacy and safety, the main observation index, secondary observation indexes, safety evaluation indexes, and the incidence of postoperative adverse reactions will be recorded and compared between the two groups.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 212 (actual)
- First submitted
- 26 Aug 2022
- Start date
- 1 Jan 2023
- Primary completion date
- 30 Jun 2023
- Lead sponsor
- The Third People's Hospital of Chengdu
- Diseases
- Obesity
- NCT number
- NCT05522998
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 212
- From 1 Jan 2023 to the primary completion date, 30 Jun 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Those who participated in any clinical trial as subjects within 3 months before enrollment;
Other illness
- Accompanied by infectious heart disease such as myocarditis or endocarditis, septicemia;
- Brain injury, possible intracranial hypertension, cerebral aneurysm, cerebrovascular accident history and central nervous system diseases: mental system diseases (schizophrenia, mania, insanity, etc.) and long-term history of taking psychotropic drugs, or other diseases that hinder the measurement of BIS value;
- Have a history of drug abuse and alcoholism within 2 years before the screening period. Alcoholism is defined as regular drinking for more than 14 times / week (once =150 ml wine or 360 ml beer or 45 ml spirits);
- Known or suspected allergy or contraindication to various components of the study drug or other benzodiazepines, opioids, propofol, muscle relaxants, etc;
Lab values
- Acute heart failure, unstable angina pectoris, myocardial infarction within 6 months before screening, resting ECG heart rate ≤ 50 beats / min, third degree atrioventricular block and other serious arrhythmias, serious heart valve disease, QTc: male ≥ 450ms, female ≥ 470ms;
- Abnormal liver and kidney function (ALT or AST ≥ 2.5 times the upper limit of normal value, TBIL ≥ 1.5 times the upper limit of normal value), abnormal renal function (bun or urea ≥ 1.5 times the upper limit of normal value, cr\> the upper limit of normal value, or dialysis treatment within 28 days before operation), or obvious abnormal coagulation function (pt/ aptt/tt higher than the upper limit of normal value), anemia or thrombocytopenia (HB ≤ 90g/l, PLT ≤ 80 × 109/L)
- Diabetes subjects whose blood glucose was not satisfactorily controlled (fasting blood glucose ≥ 11.1mmol/l in the screening period and / or random blood glucose ≥ 13.6 mmol/l);
Other
- Contraindications to general anesthesia;
- Those whose blood pressure was not satisfactorily controlled (SBP ≥ 160mmhg and / or DBP ≥ 100 mmHg in sitting position during screening period);
- SBP in sitting position during screening period ≤ 90mmHg;
- The subjects who were judged to have difficulty in respiratory management were rated as grade IV by modified Mahalanobis score;
- Pregnant or lactating women or subjects with birth plan within 6 months (including men);
- Other circumstances determined by the researcher as unsuitable for inclusion.
Who the study is looking for
- 18 \< age ≤ 65, regardless of gender;
- ASA is classified as grade I-III;
- BMI≥35kg/m2
- Obese patients who need laparoscopic sleeve gastrectomy under general anesthesia;
- The subjects voluntarily participated in the trial and signed the informed consent.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.